Trial results for evolocumab in patients with acute myocardial infarction (MI) were posted on ClinicalTrials.gov on 2025-10-23. The Phase 2 study demonstrated that evolocumab significantly reduced LDL-cholesterol by -70.59%, compared to a -44.78% reduction in the placebo group.
Background
Acute Coronary Syndrome (ACS) patients experience increased vascular and myocardial inflammation, which correlates with LDL-C levels and adverse outcomes. Proprotein convertase subtilisin/kerin type 9 (PCSK9) levels are also elevated in ACS, potentially raising LDL-C and inducing vascular inflammation. Evolocumab is a PCSK9 antibody currently approved to lower LDL-C in certain patient populations.
Trial design
The Phase 2 study (NCT04082442), titled "Evolocumab in Patients With Acute MI," enrolled 100 participants. The trial investigated evolocumab in patients diagnosed with Acute Coronary Syndrome. Participants received either evolocumab or placebos as interventions.
Key results
The trial reported key measurements for changes in LDL-Cholesterol and inflammation:
- For "Change in LDL-Cholesterol":
- The evolocumab group showed a mean reduction of -70.59 percent change mg/dL.
- The placebo group showed a mean reduction of -44.78 percent change mg/dL.
- For "FDG-PET Imaging Analysis of Inflammation as Mean Standardized Uptake Value (SUV)":
- The evolocumab group showed a mean change of -26.21 Standardized Uptake Value (SUV) with a Standard Deviation of 22.61.
- The placebo group showed a mean change of -14.52 Standardized Uptake Value (SUV) with a Standard Deviation of 36.92.
Statistical analyses included a Wilcoxon (Mann-Whitney) test with a p-value of 0.0001, and a t-test (2-sided) with a p-value of 0.34.
What this means
The results from this Phase 2 trial suggest that evolocumab may offer a substantial benefit in reducing LDL-cholesterol levels in patients with acute myocardial infarction, significantly more than placebo. The observed reduction in inflammation, while numerically greater in the evolocumab group, did not reach statistical significance in one of the analyses. These findings support further investigation into evolocumab as a potential therapeutic option for managing lipid levels and inflammation in this high-risk patient population.
Source
The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04082442, titled "Evolocumab in Patients With Acute MI," were posted on 2025-10-23 on clinicaltrials.gov.